Lurbinectedin is a chemotherapy drug that works by inhibiting the transcription process of cancer cells. According to DrugPatentWatch [1], it was first approved in Europe in 2020 for the treatment of relapsed small cell lung cancer (SCLC). However, the effectiveness of lurbinectedin in combination with immunotherapy has also been studied.

A study published in Cancer Network [2] reported that preliminary results showed that the combination of lurbinectedin and pembrolizumab, an immunotherapy drug, was safe and effective in treating relapsed SCLC in patients who had previously received platinum-based chemotherapy. The study found that the overall response rate was 45%, and the median progression-free survival was 5.4 months.

Another article on Targeted Oncology [3] also reported similar results. The study found that the combination of lurbinectedin and pembrolizumab was well-tolerated and had promising efficacy in treating relapsed SCLC. The overall response rate was 39%, and the median progression-free survival was 5.3 months.

In conclusion, preliminary results suggest that the combination of lurbinectedin and pembrolizumab is safe and effective in treating relapsed SCLC. However, further studies are needed to confirm these findings and determine the optimal dosing and duration of treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.cancernetwork.com/view/preliminary-results-show-second-line-lurbinectedin-plus-pembrolizumab-safe-effective-in-relapsed-sclc
[3] https://www.targetedonc.com/view/second-line-lurbinectedin-plus-pembrolizumab-is-safe-and-effective-in-relapsed-sclc